Advertisement

Search Results

Advertisement



Article Topics

Your search for Michael Pfreundschuh, MD matches 6 pages

Showing 1 - 6


leukemia
lymphoma

Michael Pfreundschuh, MD, on Treating Lymphoid Malignancies in Children and Adults With the Same Protocols

Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.

lymphoma

Benefit of Extended Rituximab Exposure in Poor-Prognosis Elderly Patients With Diffuse Large B-Cell Lymphoma

In the phase II SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group reported in the Journal of Clinical Oncology, Pfreundschuh et al found that extended rituximab (Rituxan) exposure in patients aged > 60 years with poor-prognosis diffuse large B-cell lymphoma was...

lymphoma

Vitamin D Deficiency Worsens Response to Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

In a study reported in the Journal of Clinical Oncology, Bittenbring et al found that vitamin D deficiency was associated with poorer outcome in older patients receiving R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) for diffuse large B-cell lymphoma...

lymphoma

No Apparent Benefit of Rituximab After Lymphoma-Directed Conditioning and Allogeneic Stem Cell Transplantation for Relapsed/Refractory Aggressive NHL

In an open-label phase II trial reported in The Lancet Oncology, Glass et al examined the strategy of adding rituximab (Rituxan) to standard prophylaxis for graft-vs-host disease after allogeneic stem cell transplantation in relapsed or refractory aggressive non-Hodgkin lymphoma. Rituximab did not...

lymphoma

Radiotherapy for Bulky Disease Added to R-CHOP Improves Outcome in Elderly Patients With Aggressive B-Cell Lymphoma

In an analysis reported in the Journal of Clinical Oncology, Held et al studied elderly patients with aggressive B-cell non-Hodgkin lymphoma and bulky disease in the most effective treatment arm of the RICOVER-60 trial, which included radiotherapy. The investigators compared outcomes ...

lymphoma

Addition of Rituximab Does Not Improve Outcome in Aggressive B-Cell Lymphoma With Skeletal Involvement, but Radiotherapy Benefit Found

In a retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in Journal of Clinical Oncology, Gerhard Held, MD, of Saarland University Medical School in Homburg, and colleagues assessed the impact of rituximab (Rituxan) and radiotherapy on outcome in patients...

Advertisement

Advertisement



Advertisement